Bel voor een afspraak:
088 75 569 01

ONGOING INVESTIGATIONS

ROLL study in Oncology Magazine

The ROLL study was designed to evaluate whether the so-called radio guided occult lesion localization (ROLL) is a good alternative to the now prevailing gold standard, the wire-guided excision (WGL) in the surgical treatment of breast cancer to feel. In the Oncology Magazine of May 2010 an informative article about the trial ROLL was published. It describes the ROLL procedure and how the study has so elapsed hitherto.

Click here to read the article.

LIMA 2

Patients with a relatively small invasive tumour (<2cm) will receive treatment with radio frequency ablation (RFA) directly prior to the surgical excision. Subsequently, the tumour will be excised. In this study, it is investigated whether the RFA procedure is effective enough to treat patients with a small breast tumour. Possibly, these small tumours will eventually no longer need surgical treatment, but can be treated with this technique only.

INTENSE Study

In this study, women with a large malignant tumour of the breast with suspected spread to the axillar lymph nodes receive chemotherapy prior to surgery. Two different schemes of chemotherapy are compared with each other. One half of the women will get a so-called AC treatment (the standard treatment) and the other half of the women will get a so-called TAC treatment (the new chemotherapy) prior to surgery.

Click here to read the article

IDEAL Study

This study investigates whether it is useful to treat breast cancer patients who have been treated with surgery and 5 years hormonal treatment for an extra 2,5 or 5 hormone treatment. Patients will be divided into two groups, one group will receive letrozole for a duration of 2.5 years, the other group will receive letrozole for a duration of 5 years.

Click here for Patientinformation IDEAL study

DATA Study

This study investigates the optimal treatment duration in patients who have had breast surgery and hormone treatment. Patients who have had 2-3 years of tamoxifen usually switch to an aromatase inhibitor, which they will also use 2-3 years. In this study, the half of the patients will receive the aromatase inhibitor for a duration of 3 years and the other half for a duration of 6 years.

Click here for Patientinformation_DATA study

Comments are closed.